GB263T
Showing 1 - 25 of 3,440
NSCLC, Other Solid Tumors Trial in Australia (GB263T)
Recruiting
- NSCLC
- Other Solid Tumors
- GB263T
-
Saint Leonards, New South Wales, Australia
- +3 more
Aug 3, 2022
Pancreatic Cancer Trial in ShangHai (TCR-T Cells Injection(GB3010 Cells Injection))
Recruiting
- Pancreatic Cancer
- TCR-T Cells Injection(GB3010 Cells Injection)
-
ShangHai, Shanghai, ChinaRuijin Hospital Affiliated to Shanghai Jiaotong University Schoo
Sep 19, 2023
Asthma Trial in Edegem (Test product (T):CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI, Reference product 1 (R1): CHF 5993 BDP/FF/GB
Recruiting
- Asthma
- Test product (T):CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI
- +2 more
-
Edegem, Antwerpen, BelgiumSGS Belgium NV - Clinical Pharmacology Unit
Jun 1, 2023
Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem
Recruiting
- Acute Myeloid Leukemia (AML)
- Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)
- gilteritinib
- +3 more
-
Cincinnati, Ohio
- +18 more
Jan 20, 2023
Severe Obesity Trial in Sweden (gastric bypass, Sleeve gastrectomy)
Active, not recruiting
- Severe Obesity
- gastric bypass
- Sleeve gastrectomy
-
Tønsberg, Norway
- +20 more
Sep 14, 2022
Peripheral T Cell Lymphoma Trial in Beijing (GB226)
Recruiting
- Peripheral T Cell Lymphoma
- GB226
-
Beijing, Beijing, ChinaCancer Hospital Chinese Academy of Medical Sciences
Mar 2, 2021
Global, Multicentre, Non Interventional Advagraf Conversion
Completed
- Kidney Transplantation
-
Camperdown, New South Wales, Australia
- +128 more
Nov 10, 2022
Advanced Hepatocellular Carcinoma Trial in Worldwide (Enzalutamide, Placebo)
Completed
- Advanced Hepatocellular Carcinoma
- Enzalutamide
- Placebo
-
San Francisco, California
- +37 more
Feb 18, 2022
Warm Autoimmune Hemolytic Anemia (wAIHA) Trial in Worldwide (parsaclisinib, )
Recruiting
- Warm Autoimmune Hemolytic Anemia (wAIHA)
- parsaclisinib
- placebo
-
Los Angeles, California
- +52 more
Nov 15, 2022
Recurrent DLBCL, Refractory DLBCL Trial in Sacramento (Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine
Recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Chimeric Antigen Receptor T-Cell Therapy
- +3 more
-
Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
Mar 8, 2022
Hematopoietic Cell Transplantation Recipient, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in
Active, not recruiting
- Hematopoietic Cell Transplantation Recipient
- +3 more
- Allogeneic Bone Marrow Transplantation
- +10 more
-
Houston, TexasM D Anderson Cancer Center
Aug 18, 2022
HIV Trial in Worldwide (Darunavir (DRV) 800 milligram (MG) Oral Tablet, Ritonavir 100 MG Oral Tablet, N(t)RTIs)
Recruiting
- HIV Infections
- Darunavir (DRV) 800 milligram (MG) Oral Tablet
- +6 more
-
Chennai, India
- +6 more
Aug 30, 2021
Recurrent DLBCL, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory DLBCL Trial in Houston (drug, procedure, other, biological)
Recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- +4 more
- Busulfan
- +7 more
-
Houston, TexasM D Anderson Cancer Center
Sep 22, 2022
Steroid-Refractory Acute GVHD Trial in Worldwide (T-Guard, Ruxolitinib)
Terminated
- Steroid-Refractory Acute Graft Versus Host Disease
-
Birmingham, Alabama
- +47 more
Jan 22, 2023
Pulmonary Artery Hypertension Trial in Worldwide (GB002 (seralutinib), Placebo, Generic Dry Powder Inhaler)
Active, not recruiting
- Pulmonary Artery Hypertension
- GB002 (seralutinib)
- +2 more
-
Phoenix, Arizona
- +64 more
Aug 17, 2022
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric
Active, not recruiting
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer
- +3 more
- zolbetuximab
- +4 more
-
Phoenix, Arizona
- +219 more
Aug 16, 2022
Type 2 Diabetes Trial in Worldwide (Tirzepatide, Semaglutide)
Completed
- Type 2 Diabetes
-
Birmingham, Alabama
- +126 more
Jan 21, 2022
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, Recurrent Acute Lymphoblastic
Active, not recruiting
- Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- +6 more
- Dexamethasone
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Dec 2, 2022
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Recurrent B Acute
Recruiting
- B Acute Lymphoblastic Leukemia
- +2 more
- Dasatinib
- +4 more
-
Portland, OregonOHSU Knight Cancer Institute
Dec 16, 2022
Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
Recruiting
- Recurrent B Acute Lymphoblastic Leukemia
- +3 more
- Cyclophosphamide
- +9 more
-
Houston, TexasM D Anderson Cancer Center
Nov 2, 2022
Leukemia, Acute Myeloid (AML) Trial in Worldwide (gilteritinib, LoDAC (Low Dose Cytarabine), Azacitidine)
Active, not recruiting
- Leukemia, Acute Myeloid (AML)
- gilteritinib
- +4 more
-
Birmingham, Alabama
- +125 more
Aug 9, 2022
Adrenal Androgens on Gender-typed Behavior in Girls With Turner
Not yet recruiting
- Turner Syndrome
- the correlation between level of adrenal androgen and gender-typed behavior in Girls with TS
-
Sohag, EgyptSohag University Hospital
Apr 25, 2022
Helicobacter Pylori Infection Trial in Jinan (Tetracycline 500mg tid, Tetracycline 500mg qid)
Recruiting
- Helicobacter Pylori Infection
- Tetracycline 500mg tid
- Tetracycline 500mg qid
-
Jinan, Shandong, ChinaDepartment of Gastroenterology,QiLu Hospital,Shandong University
Mar 25, 2023